



# 2020 Annual Results Presentation

March 31 2021



# Disclaimer



This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only.

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") before reading or making any other use of this document. In accepting the delivery of, reading or making any other use of this document, you acknowledge and agree to be bound by the Terms, and you agree to maintain absolute confidentiality regarding the information disclosed in this document in a manner consistent with the Terms. If you do not accept any of the Terms, in whole or in part, please immediately return this document to the Company.

These materials, and any further information made available to you, are highly confidential and are being given solely for your information. These materials, and any further information made available to you, form part of the proprietary information of the Company and may not be copied, reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any manner and for any purpose without the prior written consent from the Company. Any forwarding, distribution or reproduction of this document, in whole or in part, is unauthorized.

The information used in preparing this document has not been independently verified and has not been reviewed by any regulatory authority in any jurisdiction. This document does not purport to provide a complete description of the matters to which it relates. No representation, warranty or undertaking, express or implied, is or will be made or given by, and no responsibility or liability is or will be accepted by, any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this document or its contents or any oral or written communication in connection with this document. In addition, any analyses included herein are not and do not purport to be complete or comprehensive and are not and do not purport to be appraisals of the assets, stock or business of the Company or any of its holding companies, subsidiaries or other affiliates. Even when these materials contain a form of appraisal, it should be considered as preliminary, suitable only for the purpose described herein, subject to assumptions and not be disclosed or otherwise used without the prior written consent of the Company. The information in this document does not take into account the effects of a possible transaction or certain transactions which may have significant valuation and other effects. Nothing contained in this document is, or shall be, relied upon as a promise or representation as to the future or as a representation or warranty otherwise.

Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any regulatory, valuation, legal, tax, accounting, investment, or other advice. Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any recommendation, solicitation, offer or commitment to purchase, sell, subscribe for or underwrite any securities by any party, or to extend any credit or provide any insurance to you or to enter into any transaction, nor shall there be any sale of securities or other transaction in any jurisdiction in which such sale or transaction would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. None of the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

The contents of this document are subject to corrections or changes at any time without further notice. The information contained in these materials also contains certain forward-looking statements regarding the Company's intent, plans, beliefs, strategies, and growth prospects as well as the projected growth of China's economy and the pharmaceutical industry, which are based on various assumptions and subject to risks and uncertainties. In light of these assumptions, risks, and uncertainties, the future facts, events and circumstances described in these materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements are not guarantees of future performance. Each of the Company and its and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to (1) provide access to any additional information, (2) correct any mistakes or inaccuracies in this document, or (3) update or otherwise revise this document, for any reason whatsoever, including without limitation to reflect new information, events or circumstances that arise, occur or become known after the date of this document.

By receiving or reading this document, you acknowledge and represent to the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisors that (1) you are a "professional investor" as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, and (3) you have conducted and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company, and, if located in the United States, are either a "qualified institutional buyer" or an institutional "accredited investor" as defined in the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder (the "U.S. Securities Act").

No information set out in this document will form the basis of or be relied upon in connection with any contract, commitment or investment decision. Any prospective investor will be required to acknowledge in any purchase contract that it has not relied on, or been induced to enter into such agreement by, any representation or warranty, save as expressly set out in such agreement. This document does not constitute, in whole or in part, an offer or invitation for the sale, purchase or subscription of any security. Any such offer or invitation will be made solely through a prospectus or offering circular in compliance with all applicable laws and any decision to purchase or subscribe for any security should be made solely on the basis of the information contained in such prospectus or offering circular issued in connection with such offer or invitation.

This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of the U.S. Securities Act; (2) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (3) to have effected an offer to the public in the United States, Hong Kong or anywhere else without compliance with all applicable laws and regulations or being able to invoke any exemption available under all applicable laws and regulations and is subject to material change without notice. The distribution of this document may be restricted by law, and persons into whose possession this document comes should inform themselves of, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable securities laws. The Company does not intend to conduct any public offering of securities in the United States, Hong Kong or anywhere else.

# Content



- **2020 Highlights**
- **R&D & Pipeline**
- **Financial Performance**
- **Q & A**



# 2020 Highlights



**Chairman, Director and CEO**  
**Dr. Jing LOU**



# Performance Summary



**Revenue**  
increased YOY 5.1% to RMB5,587 million




**TIPAIQ**  
sales yoy  
increased **19%** to  
**RMB2,763**  
**million**



**rhEPO**  
EPO & SEPO  
sales yoy  
increased **30%**  
to **RMB974**  
**million**




**MANDI**  
sales yoy  
increased **47%**  
to **RMB368**  
**million**



**YISAIPU**  
sales yoy  
reduced **46%** to  
**RMB615 million**

## Adjusted Normalized Net Profit Attributable to Owners of the Parent

RMB million



\*Exclude diabetic business and loss of currency exchange

# 2020 Highlights



## R&D

- **302H (HER2)** NDA approval and product launched to the market
- **601A (VEGF)** AMD and DME completed the patient enrollment in phase I trial, RVO and mpCNV initiated the preparation of Phase II clinical trial
- **602 (EGFR)** entered into Phase II clinical trial
- **609A (PD1)** completed the patient enrollment in Phase I in U.S. and proceeding patient enrollment in Phase I in China
- **608 (IL-17A)** completed patient enrollment in Phase I and preparing for Phase II clinical trial
- **610 (IL-5)** IND approved and completed patient enrollment in Phase Ia
- **611 (IL-4)** IND approved by FDA and NMPA, patient enrollment in Phase Ia in U.S.
- **SSS06 (rESP)** completed patient enrollment in Phase II clinical study
- ~6 small molecules entered into BE
- **Shanghai Guojian Digital Factory** construction work almost complete
- **Construction of the 3<sup>rd</sup> workshop of Shenyang Base** was accomplished and entered into equipment testing process
- Phase I of **CDMO Project in Shenyang Desheng** is progressing smoothly and about to commence the Phase II
- **Construction of the R&D and CDMO Base in Shenzhen Songshan Lake** entered into the final stage



## Manufacture



## Sales

- **Sales Network:** **3,263** sales and marketing employees, **797** distributors, and **2,263** third-party promoters
- **NRDL: TPIAO** sales **increased 19%**, national negotiation within expectation; **Cipterbin** was approved, launched, and successfully be included into NRDL in within the same year
- **rhEPO** sales rebounded to **RMB974 million**
- **Mandi** sales **yoy rises of 47%** to **CNY368 million** as the online revenue soared **~100%**



## Collaboration



Co-developed 5 kinds of multi-specific antibodies and about to import the **1st** type of antibody



Selected **VSIG-4** and **PSGL-1** targeted antibodies partnered MCM in immuno-oncology and commenced pre-clinical study



**Remitch (TRK-820)** almost completed the patient enrollment of Phase III bridging trial



**Pegsiticase** entered into Phase III clinical trial in U.S. and received **US\$4 million milestone fee**



Invested in GenSight, a world leading gene therapy specialized in ophthalmology company, and its core products have been approved and filed NDA in Europe

- **MSCI ESG Rating** from BBB to **A** and surpassed **78%** global biotech companies

# Core Products Maintained Significant Growth



Product	Sample	Revenue (RMB million)	YoY %
TIPAO		2019: 2,323 2020: 2,763	19%
EPO & SEPO		2019: 749 2020: 974	30%
YISAIPU		2019: 1,144 2020: 615	(46%)
MANDI		2019: 250 2020: 368	47%
Others <sup>1</sup>		2019: 852 2020: 863	2%



1. Except for the above four core products, there are other products including but not limited to Sparin (injectable low-molecular-weight heparin calcium), Aiyishu (Iron sucrose), and Humulin (recombinant insulin) which had exceeded over RMB100 million sales in 2020.



## Performance


- Sound sales growth to **RMB2,763 million** yoy increased **19%** to a new level
- First-to-market and the only commercialized rhTPO product in the world which is recommended by more than **4** Chinese Experts Consensus<sup>1-4</sup> as **the first-choice** recommendation for boosting platelet in China
- Sales value with a dominated leading position as the market share of **72.7%**<sup>5</sup>
- National Hospital Ranking **Top 11** vs Top 15 in 2019



1. Recommended by *Chinese Expert Consensus on Prevention and Treatment of CIT in Malignant Lymphoma*  
 2. Recommended by *The Expert Consensus for Diagnosis and Treatment of Thrombocytopenia in Adult Critical Illness in China*

## Outlook

### Multiple Driving Forces Boost Growth with the Anticipation of RMB5 Billion Peak Sales



3. The first-choice recommendation for boosting platelet production as Recommended by *The Expert Consensus for Diagnosis and Treatment of Thrombocytopenia in China*  
 4. Recommended drugs for emergency treatment of children with ITP in the *Guidelines for the Diagnosis and Treatment of Primary Immune Thrombocytopenia in Children*  
 5. Source: IQVIA 2020 and the market definition includes rhTPO, IL-11, and oral treatments

# rhEPO (EPO & SEPO)



## Performance

- Sales rebounded yoy **30%** to **RMB974 million**
- Acceleration in the applications of EPIAO in IV and V CKD patients and in CIA oncology indication in Mainland China due to the benefit of NRDL coverage
- A product of National Essential Medicines List (NEML) with a steady incremental penetration rate in the grassroots market domestically
- Dual-brand strategy stabilized the pricing system
- Market share consistently ranked **Top 1**



## Outlook

### Brand Image & Production Capacity Reinforce the Competence While Combination of Innovation and Imitation Extend Products Lifespan

#### Expansion of Production Capacity

Newly built facilities in Shenyang and Shenzhen supports the future demands generated from national and provincial VBP

04

#### Advance NRDL and NEML benefits

- Continue to solve the NRDL coverage of the reduction of allogeneic blood transfusion in surgery patients
- Strengthen the implementation of NEML

#### Long-acting products Iteration

Deployed two types of long-acting products to lengthen product the life cycle

03

01

02

#### Product Synergy

- Intend to file NDA of oral treatment Roxadustat in 2023
- Self-developed SSS17HIF is in Phase I clinical trial


1. Source: IQVIA 2020 and the market definition includes rhEPO and oral treatments.



## Performance

- Dual impact of COVID-19 pandemic and fierce competition, sales slumped **46%** to **RMB615 million**
- New patients increased after Initiated 50% price cut while the DOT was extended within the existing patients. A significantly growth showed in sales volume in Q4 2020
- Currently covered **3,700** hospitals and medical institutes, including Tier 1 hospitals **~1,700**
- Market Share in TNF $\alpha$  remained **Top 1**
- Accumulated treated over **few hundred thousands** patients


RMB million



## Outlook

### Promote County Level Strategy, Accelerate Penetration to Expand Incremental Market

- The number of domestic patients of RA in the grassroots hospitals boosted from **17%** in 2010 to **49%**<sup>2</sup> in 2019



- Domestic DMARDS utilization rate is extremely lower than well-developed countries<sup>3</sup>



1. Source: IQVIA 2020

2. Source: Wind, National Bureau of Statistics

3. Source: 2018 Rheumatoid Arthritis Treatment Guidelines

# CIPTERBIN




## Performance

- Approved by CDE and was included in NRDL **in the same year**
- Self-developed, **China first innovated** under the **new label Inetetamab** was included in **Clinical Guidance**<sup>1</sup> and **Chinese Experts Consensus**<sup>2</sup> after launching to the market

### Stronger ADCC Effect

- Engineered FC region performs better **ADCC effect**, decelerates the clinical progression of HER2+ breast cancer patients.



3

### Less Immunogenicity

- Optimized production process: the impurity aggregate is a dimer, which provides **less risk of immunogenicity** comparing with trastuzumab's trimer impurity, and safer for a long-term clinical treatment

### Various HER2 Layout

- Various HER2 layout including **new anti-HER2 antibody, combo therapy, bispecific antibody, multi-specific antibody, new immunotherapy targets**

## Outlook


Seize the opportunity of NRDL, Position in the Core Track, and Estimated Peak Sales reach RMB1.5 billion

Successfully be included in NRDL with a competitive price to end users

Completed 140+ core hospital entrance

Develop multiple varieties & comb therapy

- Develop innovative anti-HER2 drug resistance treatments, accumulate real-world data from precision treatments, and layout future indications roadmap



1. Source: *The Principle of Innovative Anti-tumor Drug Clinical Guidance (2020)* issued by China National Health Commission

2. Source: *China Advancing Period of Breast Cancer Experts Consensus Guidance 2020 (CABC3)*

3. The chart indicates the test result of HER2 positive breast cancer patients after taking the treatment of Cipterbin

4. Source: *Frost & Sullivan*



## Performance

- Sales surged yoy **47%** to **RMB368 million**
- Market share took up **75%**, occupied the absolute dominate position
- Online sales yoy soared **~100%**, Ranked **Top 1** in the same category


Online Platform	Therapeutics	Ranking
 京东	Dermatology	1
 天猫	Hair loss Treatment	1

RMB million



## Outlook

### Take a Lead in the Hair Loss Frontier Segment and Aesthetic Medicine Enhances Peak Sale Expectation



1 Source: CPA 2020


# Multiple Catalysts Expedite Sustainable Growth in the Recent 2-3 Years



**01** **TPIAO** National Negotiation for 2021 NRDL had been done. A unique and exclusive product with a rigid clinical demand, and continues to accelerate the penetration rate in clinical usage

**02** **rhEPO**'s dual-brand strategy reinforces the market share in 2020 while the capacity expansion of Shenzhen and Guangdong bases ensures low-cost supply

**03** **YISAIPU** The impact of COVID-19 pandemic has almost been eliminated and the sales is gradually recovering. Stick to implement the sinking strategy, and improve the increase the penetration rate.



**04** **Cipterbin** seizes the benefit of NRDL

**05** **Mandi** combines with hospital resources, strengthens online promotion efforts, and makes the most of brand advantage.

**06** **New products** Remitch, Minoxidil Foam type, Amphotericin B Liposome, and numbers of small molecules will be launched within 2-3 years for more incremental sales

<sup>1</sup> YISAIPU: If the price remains stable in 2020, a 30%+ revenue increase of revenue may be achievable and a double digits growth in the next 2-3 years.



# R&D and Pipeline



**Sunshine Guojian President**  
**Dr. Zhenping ZHU**



# R&D Progress



- **302H (HER2)** NDA approval and product launched to the market
- **304R (CD20)** in the progress of Phase III trial site inspection
- **602 (EGFR)** entered into Phase II clinical trial
- **609A (PD1)** completed the patient enrollment in Phase I in U.S. and proceeding patient enrollment in Phase I in China
- **612 (HER-2)** Filed IND
- **705 (Bispecific)** Filed Pre-IND



Selected **VSIG-4** and **PSGL-1** targets partnered MCM in immuno-oncology for the China domestic authorization and commenced pre-clinical study



- **608 (IL-17A)** completed patient enrollment in Phase I
- **610 (IL-5)** IND approved and completed patient enrollment in Phase Ia clinical trial
- **611 (IL-4)** IND approved by FDA and NMPA, and proceeding patient enrollment in Phase Ia clinical trial in U.S.
- **613 (IL-1 $\beta$ )** Filed Pre-IND
- **Equity Investment:**



Core product GS010 have been approved and filed NDA in Europe



Core product SENS401 is proceeding Phase II clinical trial of SSNHL<sup>1</sup> and pre-clinical studies multiple preventive indications

- **SSS17 (HIF-117)** initiated patient enrollment of Phase I clinical trial
- **SSS06 (rESP)** completed patient enrollment in Phase II clinical trial
- **RD001 (rESP)** proceeding patient enrollment in Phase II clinical trial
- **TPIAO (rhTPO)** completed surgery patients with hepatic dysfunction at the risk of thrombocytopenia Phase I trial and recruiting patients for pediatric ITP Phase III clinical trial



**Remitch (TRK-820)** almost completed the patient enrollment of Phase III bridging trial




**Pegisitacase** entered into Phase III clinical trial in U.S. and received **US\$4 million milestone fee**

# Robust and Innovative Product Pipeline




# Biologics Pipeline in Oncology



Product	Target	Indication	Pre-clinical	IND	Phase I	Phase II	Phase III
304R	CD20	NHL					
602	EGFR	Colorectal Cancer					
609A	PD1	NSCLC, Gastric and Liver Cancer					
615	VEGF	Multiple Cancer					
612	HER2	Breast and Gastric Cancer					
705	BsAb1	Metastatic Breast Cancer, Gastric Cancer					
706	BsAb3	Solid Tumor					
707	BsAb4	Solid Tumor					
617	PSGL-1	Multiple Cancer					
6xx	VSIG4	Multiple Cancer					

- Independent Development of Bispecific Antibody Platform  
 - Effectively Avoid Mismatching  
 - Dual Filing in U.S. and China

## HER-2 Layout



# Biologics Pipeline in Nephrology, Auto-immune, and Others



Therapeutic	Product	Target	Indication	Pre-Clinical	IND	Phase I	Phase II	Phase III	NDA
Auto-immune	301S	TNF $\alpha$	RA, PS, AS	[Progress bar]					
	SSS07	TNF $\alpha$	RA, AS, Ulcerative colitis	[Progress bar]					
	610	IL5 $\alpha$	Asthma, COPD	[Progress bar]					
	613	IL1b	Multiple auto-immune diseases	[Progress bar]					
	SB16	RANKL	Bone diseases <sup>2</sup>	[Progress bar]					
Dermatology	608	IL17A	PS, AS, Psoriatic arthritis	[Progress bar]					
	611	IL4R $\alpha$	Atopic dermatitis, Asthma	[Progress bar]					
Nephrology	TPO	-	Pediatric ITP	[Progress bar]					
	TPO	-	Surgery patients with hepatic dysfunction at the risk of thrombocytopenia	[Progress bar]					
	SSS06	EpoR	Anemia associated with CKD	[Progress bar]					
	RD01	EpoR	Anemia associated with CKD	[Progress bar]					
Ophthalmology	SSS11	Uric Acid	Hyperuricemia, Refractory gout	[Progress bar]					
	601A	VEGF	Ophthalmologic diseases (AMD, DME, RVO, pmCNV)	[Progress bar]					

## FOCUS ON GLOBAL BLOCKBUSTER

**608**

- New amino acid sequence targeting IL-17A
- Global sales of Secukinumab with the same target is approximately **US\$4 billion** in 2020

**611**

- New amino acid sequence targeting IL-4R $\alpha$
- Dual filing in both U.S. and China
- Global sales of Duplizumab with the same target exceeded **US\$4 billion** in 2020

**610**

- New variable region sequence antibody targeting IL-5
- The **1<sup>st</sup>** domestic application and no similar launched product in China
- Global sales of Mepolizumab with the same target exceeded **US\$1.2 billion** in 2020

**601A**

- Global multi-center clinical trials
- **4 indications** clinical trials are progressing with a full coverage of ophthalmology

1. Source: Global sales of each drug are consolidated from public data

2. Postmenopausal female with osteoporosis at high fracture risk

# Small Molecule Combo



## Nephrology



### Sevelamer Carbonate (SSS13)

- Oral treatment of Hyperphosphatemia
- NDA filed in 2020

### Cinacalcet Hydrochloride (SSS12)

- Oral treatment of Hyperthyroidism
- NDA: 2021

### Roxadustat (SSS38)

- Oral treatment of rhEPO which included into the Top Notch Guidance as recommendation, creates synergy with **EPO**
- NDA: 2023

## Auto-immune



### Apremilast (AP506)

- Oral treatment of PS and Psoriatic Arthritis
- Synergy: **YISAIPU**
- NDA: 2021

### Tofacitinib (SSS32)

- Oral treatment of RA
- Synergy: **YISAIPU**
- NDA: 2021

### Eltrombopag (SSS20)

- Oral treatment of ITP creates synergy with **TPIAO**
- NDA: 2021

## Oncology



### Trifluridine and Tipiracil Hydrochloride Tablets (SSS24)

- Oral treatment of Colorectal Cancer
- Synergy: SB8, 602
- NDA: 2022

## Dermatology



### Minoxidil Foam (MN709)

- Foam Type
- Synergy: **MANDI**
- NDA: 2021

### Apremilast (AP506)

- Indication: PS
- Synergy: **YISAIPU**

# Integrated International Strategic Collaborations



## Oncology



- China rights of Bevacizumab biosimilar named **SB8**



- Two selected Verseau's **PLGS-1** and **VSIG-4** targeted antibodies in immuno-oncology collaborations for future development and commercialization of Great China Region <sup>1</sup>



- Co-developed 5 kinds of multi-specific antibodies and responsible for the development and commercialization of Greater China region<sup>1</sup>



- Cooperative development and commercialization of CAR-T cell therapies

## Dermatology



- China Rights of **Amphotericin B Liposome**



- AI early diagnosis and screening of **ophthalmologic** diseases

## Nephrology



- American right of **Pegsiticase** specialized in hyperuricemia, and refractory gout



- China rights of **Remitch (TRK-820)** for the treatment of pruritus in hemodialysis patients

## Gene Therapy



- Invested in GenSight, a world leading gene therapy specialized in ophthalmology company, and its core products have been approved and file NDA in Europe




- Cooperated with Sensorion, the world's leading new therapy company for inner ear diseases, and obtained the pre-emption right to buy its products in Greater China

1. Great China Region includes China mainland, Hong Kong, Macau, and Taiwan

# R&D Outlook



## Estimation in 2025



	601A (RVO/pmCNV)	611	612	613	705,706,707	617	VSIG-4	SSS17
Estimated Peak Sales (RMB bn)	16 <sup>1</sup>	30	10	30	30	10-20	-	15 <sup>2</sup>

	601A (DME)	602	609A (China)	610	SB16	RD001	SSS06	Other possible candidates
	16 <sup>1</sup>	5	15 <sup>3</sup>	15	-	20 <sup>2</sup>	20 <sup>2</sup>	

	TPIAO <sup>4</sup>	Remitch	301S	304R	615	608	609A (U.S.)	601A (AMD)	>10 small molecule biosimilar
	-	-	-	10-13	6	15	15 <sup>3</sup>	16 <sup>1</sup>	

	TPIAO	EPO	Mandi	Yisaipu	Cipterbin	Xenopax	Ampholipad	Existed launched products
	50	20 <sup>2</sup>	10	30	15	2	15	

1. Total peak sales for all indications covered by 601A
2. Total peak sales for rhEPO products
3. Total peak sales for all indications covered by 609A
4. Indications of Pediatric ITP and relevant liver diseases for TPIAO

# Integrated R&D Centers and Platforms



**Shenyang  
Biologics/Chemicals**



**Shanghai  
Biologics**



**Shenzhen  
Biologics**



**Hangzhou  
Chemicals**



Key technical links ie. animal immunity, cell fusion, automated high-throughput screening, and antibody characterization analysis

**Hybridoma Technology Platform**



- National Engineering Research Center for Antibody Drugs
- Multiple Research Programs Supported by 13th Five-Year Major Drug Development Project



Molecular construction platform + Protein expression and purification platform + Biological activity platform

**Antibodies and Proteins Engineering Integrated Platform**

- An integrated biopharmaceutical platform for research, production and marketing



The world-class structural characterization hardware platform meets the needs of antibody drug R&D and application of structure characterization

**Protein Characterization Analysis Platform**



Large-scale high-density cultivate specialized in technology platform for mammalian cells

**Pilot-test Process of Original Solution Development and GMP Production Platform for Clinical Drugs**

- 70+ national patents, 30+ launched products, • 34 product candidates, among which we have 24 National Class I New Drugs



Medium technology platform + Protein A affinity chromatography packing technology platform

**Key Production Raw Material Technology Platform**



Development experience of high-concentration antibody, bispecific antibody, and other macromolecular injection formulations

**Bio-macromolecule Drug Preparation Development Platform**



- 500+ experienced scientists

# Comprehensive Manufacturing Capabilities Adhere to Int'l Quality Standards



- Hangzhou**
  - All 10 production lines for different dosage forms are certified by GMP in 2010
  - QA personnel represent 20%+ of all manufacturing employees at the site
  - General manager has 10+ years' experience of pharmaceutical R&D, manufacturing and quality control
- Suzhou**
  - Suzhou High-Tech Park Future CMO Facility
- Italy**
  - Serves world-renowned companies such as Mylan and Sanofi
  - QA personnel represent nearly 40% of all manufacturing employees at the site
  - EU GMP certified production lines in Italy
- Shenzhen**
  - All existing and new production lines were granted GMP certification in 2013 and in 2016
  - QA personnel represent 20%+ of all manufacturing employees at the site
  - QA director has 10 years' experience of pharmaceutical R&D, manufacturing and quality control
- Dongguan Song Shan Lake**
  - Shenzhen Song Shan Lake Facility(EPO, R&D, CDMO )
- Shenyang**
  - Plant certified by 11 countries, including Ukraine, Brazil and Mexico
  - QA personnel represent 20%+ of all manufacturing employees at the site
- Shenyang De Sheng**
  - Future CDMO production capacity over 100,000 liters
- Shanghai**
  - Plant certified by countries including Colombia, Brazil, Mexico and Ukraine
  - Passed EU QP audit
  - QA personnel represent 20%+ of all manufacturing employees at the site
- Shanghai Digital Factory**
  - Shanghai Digital Factory



# Financial Performance



Chief Financial Officer  
Mr. Fei WANG



# Main Revenue Continuously Maintains Steady Growth while Gross Profit retains 80%+



■ RMB million

### Total Revenue




### Gross Profit



### Net Profit Attributable to Owners of the Parent




### Adjusted Normalized Net Profit Attributable to Owners of the Parent



\*Exclude diabetic business and loss of currency exchange

# Continuously Invest into R&D while Sales and Management Fees are Gradually Reduced




■ Share Scheme

■ Normalized Management Fee

## Management Fee




## R&D Expense




# Significant growth of both net assets and total assets in 2020 while the debt to asset ratio continuously decreases




■ Total asset RMB billion



■ Net asset RMB billion




Debt to asset ratio (%)





# Excellent Cash Flow and Abundant Cash Reserves

Operation cash flow (RMB billion)



Cash and cash equivalents (RMB billion)  
(including financial products)





# Q & A



**Management Team**





# THANKS

**3SBio Inc. (1530.HK)**  
**Investor Relations**  
**[ir@3sbio.com](mailto:ir@3sbio.com)**

珍爱生命 · 关注生存 · 创造生活  
CHERISH LIFE CARE FOR LIFE CREATE LIFE